Dipeptidyl peptidases and inflammatory bowel disease.
Abbott
Catherine A
CA
School of Biological Sciences, Flinders University, Adelaide, SA, Australia.
Yazbeck
Roger
R
Geier
Mark S
MS
Demuth
Hans-Ulrich
HU
Howarth
Gordon S
GS
D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016264:Dextran Sulfate / Q000633:toxicity; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D004195:Disease Models, Animal; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides / Q000378:metabolism; D006801:Humans; D007202:Indicators and Reagents / Q000633:toxicity; D015212:Inflammatory Bowel Diseases / Q000201:enzymology*; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000473:pathology; D007532:Isoleucine / Q000031:analogs & derivatives; D051379:Mice; D018345:Mice, Knockout; D010446:Peptide Fragments / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use
D053767:Glucagon-Like Peptide 2; D007202:Indicators and Reagents; D010446:Peptide Fragments; D015842:Serine Proteinase Inhibitors; D007532:Isoleucine; D004763:Glucagon-Like Peptides; D016264:Dextran Sulfate; D018819:Dipeptidyl Peptidase 4